🇺🇸 FDA
Patent

US 8969403

Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compound

granted A61KA61K31/40A61P

Quick answer

US patent 8969403 (Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compound) held by Theravance Biopharma R&D IP, LLC expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Mar 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/40, A61P, A61P1/00, A61P1/10